Tiansheng Pharmaceutical Group Co., Ltd.
SZSE:002872.SZ
4.97 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 579.335 | 606.992 | 736.686 | 1,202.746 | 1,678.052 | 2,171.44 | 2,261.414 | 2,086.932 | 1,843.015 | 1,663.784 | 1,421.96 | 1,004.12 |
| Cost of Revenue
| 306.568 | 263.594 | 432.703 | 852.832 | 1,206.047 | 1,548.584 | 1,578.523 | 1,474.681 | 1,308.562 | 1,202.798 | 997.769 | 715.477 |
| Gross Profit
| 272.767 | 343.398 | 303.983 | 349.914 | 472.005 | 622.856 | 682.892 | 612.251 | 534.453 | 460.987 | 424.191 | 288.643 |
| Gross Profit Ratio
| 0.471 | 0.566 | 0.413 | 0.291 | 0.281 | 0.287 | 0.302 | 0.293 | 0.29 | 0.277 | 0.298 | 0.287 |
| Reseach & Development Expenses
| 30.916 | 34.269 | 29.244 | 22.456 | 36.287 | 39.782 | 33.858 | 35.118 | 21.179 | 19.126 | 25.153 | 14.683 |
| General & Administrative Expenses
| 32.973 | 35.965 | 32.352 | 51.338 | 44.491 | 29.208 | 30.138 | 22.856 | 21.238 | 23.164 | 106.299 | 68.709 |
| Selling & Marketing Expenses
| 180.277 | 267.083 | 228.43 | 300.482 | 410.144 | 370.254 | 191.206 | 179.744 | 151.67 | 136.338 | 122.234 | 90.607 |
| SG&A
| 213.25 | 303.048 | 260.782 | 351.82 | 454.635 | 399.462 | 221.344 | 202.6 | 172.908 | 159.502 | 228.533 | 159.316 |
| Other Expenses
| -1.15 | 70.49 | 47.344 | 71.375 | 82.914 | 66.475 | 57.517 | 39.213 | 41.015 | 27.493 | 20.503 | 23.223 |
| Operating Expenses
| 337.339 | 407.808 | 337.37 | 445.651 | 573.836 | 505.72 | 312.719 | 321.155 | 269.344 | 242.898 | 234.333 | 165.18 |
| Operating Income
| -93.573 | -51.199 | -6.517 | -95.737 | -102.658 | 96.626 | 309.648 | 238.661 | 206.922 | 173.344 | 149.635 | 107.674 |
| Operating Income Ratio
| -0.162 | -0.084 | -0.009 | -0.08 | -0.061 | 0.044 | 0.137 | 0.114 | 0.112 | 0.104 | 0.105 | 0.107 |
| Total Other Income Expenses Net
| -1.15 | -32.917 | -47.927 | -438.841 | -126.979 | -59.581 | -4.398 | -14.17 | -18.509 | -17.736 | -20.95 | 7.376 |
| Income Before Tax
| -94.723 | -84.116 | -54.444 | -534.578 | -229.637 | 37.045 | 305.251 | 276.926 | 246.601 | 200.352 | 168.908 | 130.84 |
| Income Before Tax Ratio
| -0.164 | -0.139 | -0.074 | -0.444 | -0.137 | 0.017 | 0.135 | 0.133 | 0.134 | 0.12 | 0.119 | 0.13 |
| Income Tax Expense
| -1.011 | 7.437 | 17.895 | -40.993 | -10.698 | 21.424 | 49.44 | 42.882 | 45.302 | 26.482 | 35.883 | 17.635 |
| Net Income
| -93.074 | -91.553 | -72.339 | -493.585 | -218.939 | 15.621 | 248.575 | 224.497 | 191.978 | 164.573 | 125.948 | 109.988 |
| Net Income Ratio
| -0.161 | -0.151 | -0.098 | -0.41 | -0.13 | 0.007 | 0.11 | 0.108 | 0.104 | 0.099 | 0.089 | 0.11 |
| EPS
| -0.29 | -0.29 | -0.23 | -1.55 | -0.69 | 0.063 | 0.84 | 0.94 | 0.81 | 0.75 | 0.59 | 0.55 |
| EPS Diluted
| -0.29 | -0.29 | -0.23 | -1.55 | -0.69 | 0.063 | 0.84 | 0.94 | 0.81 | 0.75 | 0.59 | 0.55 |
| EBITDA
| 51.527 | 56.523 | 83.475 | -8.276 | 3.405 | 205.129 | 465.079 | 404.18 | 373.009 | 308.48 | 253.081 | 156.473 |
| EBITDA Ratio
| 0.089 | 0.093 | 0.113 | -0.007 | 0.002 | 0.094 | 0.206 | 0.194 | 0.202 | 0.185 | 0.178 | 0.156 |